BioLineRx (BLRX) Scheduled to Post Earnings on Thursday

BioLineRx (NASDAQ:BLRX) is set to issue its quarterly earnings data before the market opens on Thursday, August 15th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.28. The business had revenue of $6.86 million during the quarter, compared to the consensus estimate of $0.34 million. During the same quarter last year, the firm posted ($0.15) earnings per share. On average, analysts expect BioLineRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLineRx Price Performance

Shares of NASDAQ:BLRX traded up $0.04 during trading hours on Friday, hitting $0.72. 28,400 shares of the company’s stock traded hands, compared to its average volume of 366,609. The company’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.86. The company has a market cap of $57.55 million, a price-to-earnings ratio of -0.95 and a beta of 1.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.05 and a current ratio of 1.14. BioLineRx has a 52 week low of $0.51 and a 52 week high of $2.53.

Analyst Ratings Changes

A number of brokerages recently issued reports on BLRX. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of BioLineRx in a report on Wednesday, May 29th. StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.